Metabonomic Profiling of Serum and Urine by 1H NMR-Based Spectroscopy Discriminates Patients with Chronic Obstructive Pulmonary Disease and Healthy Individuals

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Wang, Lingling ^a   Tang, Yufu ^b   Liu, Shuo ^a   Mao, Shitao ^a   Ling, Yuan ^a   Liu, Dan ^a   He, Xiaoyu ^a   Wang, Xiaoge ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b No 202 Hospital of PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLNICOTINAMIDE; 2 OXOGLUTARIC ACID; ACETIC ACID; AMINO ACID; BRANCHED CHAIN AMINO ACID; CARNOSINE; CREATININE; GLYCEROPHOSPHORYLCHOLINE; KETONE BODY; LACTIC ACID; LIPOPROTEIN; M HYDROXYPHENYLACETATE; MANDELIC ACID; PHENYLACETYLGLYCINE; PYRUVIC ACID; UNCLASSIFIED DRUG; PHOSPHORYLCHOLINE;

ADULT; AGED; ARTICLE; BIOMICS; BLOOD ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; METABOLIC RATE; METABONOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PATTERN RECOGNITION; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; URINALYSIS; BLOOD; METABOLOMICS; MIDDLE AGED; PROCEDURES; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS; AMINO ACIDS, BRANCHED-CHAIN; FEMALE; HUMANS; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOMICS; MIDDLE AGED; PHOSPHORYLCHOLINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84878809473     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065675     Document Type: Article

References (59)

1. Mathers CD, Loncar D, (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442.
2. Beaglehole R, Yach D, (2003) Globalisation and the prevention and control of non-communicable disease: the neglected chronic diseases of adults. Lancet 362: 903-908.
3. Fang X, Wang X, Bai C, (2011) COPD in China: the burden and importance of proper management. Chest 139: 920-929.
4. Nathell L, Nathell M, Malmberg P, Larsson K, (2007) COPD diagnosis related to different guidelines and spirometry techniques. Respir Res 8: 89.
5. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, et al. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532-555.
6. Marsh S, Aldington S, Shirtcliffe P, Weatherall M, Beasley R, (2006) Smoking and COPD: What really are the risks? Eur Respir J 28: 883-884.
7. Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, et al. (2003) Not 15 but 50% of smokers develop COPD?-Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 97: 115-122.
8. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, et al. (2006) Global burden of COPD: systematic review and meta-analysis. Eur Respir J 28: 523-532.
9. Kennedy SM, Chambers R, Du W, Dimich-Ward H, (2007) Environmental and occupational exposures: do they affect chronic obstructive pulmonary disease differently in women and men? Proc Am Thorac Soc 4: 692-694.
10. Devereux G, (2006) ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors. BMJ 332: 1142-1144.
11. Gooptu B, Ekeowa UI, Lomas DA, (2009) Mechanisms of emphysema in alpha1-antitrypsin deficiency: molecular and cellular insights. Eur Respir J 34: 475-488.
12. Hogg JC, Timens W, (2009) The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 4: 435-459.
13. Decramer M, Janssens W, Miravitlles M, (2012) Chronic obstructive pulmonary disease. Lancet 379: 1341-1351.
14. Opitz B, van Laak V, Eitel J, Suttorp N, (2010) Innate immune recognition in infectious and noninfectious diseases of the lung. Am J Respir Crit Care Med 181: 1294-1309.
15. Demedts IK, Bracke KR, Van Pottelberge G, Testelmans D, Verleden GM, et al. (2007) Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 998-1005.
16. Barnes PJ, Shapiro SD, Pauwels RA, (2003) Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22: 672-688.
17. Di Stefano A, Caramori G, Gnemmi I, Contoli M, Vicari C, et al. (2009) T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol 157: 316-324.
18. Alcorn JF, Crowe CR, Kolls JK, (2010) TH17 cells in asthma and COPD. Annu Rev Physiol 72: 495-516.
19. Rahman I, Adcock IM, (2006) Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 28: 219-242.
20. MacNee W, (2005) Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 50-60.
21. Churg A, Wright JL, (2005) Proteases and emphysema. Curr Opin Pulm Med 11: 153-159.
22. Baraldo S, Bazzan E, Zanin ME, Turato G, Garbisa S, et al. (2007) Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. Chest 132: 1733-1740.
23. Nicholson JK, Lindon JC, Holmes E, (1999) 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29: 1181-1189.
24. Nicholson JK, Wilson ID, Lindon JC, (2011) Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 12: 103-111.
25. Schmidt CW, (2004) Metabolomics: what's happening downstream of DNA. Environ Health Perspect 112: A410-415.
26. Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC, (1995) 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem 67: 793-811.
27. Griffin JL, (2003) Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr Opin Chem Biol 7: 648-654.
28. Carrola J, Rocha CM, Barros AS, Gil AM, Goodfellow BJ, et al. (2011) Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res 10: 221-230.
29. Rocha CM, Carrola J, Barros AS, Gil AM, Goodfellow BJ, et al. (2011) Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J Proteome Res 10: 4314-4324.
30. Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, et al. (2005) Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 113: 782-788.
31. Duarte IF, Goodfellow BJ, Barros A, Jones JG, Barosa C, et al. (2007) Metabolic characterisation of plasma in juveniles with glycogen storage disease type 1a (GSD1a) by high-resolution (1)H NMR spectroscopy. NMR Biomed 20: 401-412.
32. de Laurentiis G, Paris D, Melck D, Maniscalco M, Marsico S, et al. (2008) Metabonomic analysis of exhaled breath condensate in adults by nuclear magnetic resonance spectroscopy. Eur Respir J 32: 1175-1183.
33. McClay JL, Adkins DE, Isern NG, O'Connell TM, Wooten JB, et al. (2010) (1)H nuclear magnetic resonance metabolomics analysis identifies novel urinary biomarkers for lung function. J Proteome Res 9: 3083-3090.
34. Ubhi BK, Riley JH, Shaw PA, Lomas DA, Tal-Singer R, et al. (2012) Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J 40: 345-355.
35. Soininen P, Kangas AJ, Wurtz P, Tukiainen T, Tynkkynen T, et al. (2009) High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 134: 1781-1785.
36. Wang J, Stancakova A, Soininen P, Kangas AJ, Paananen J, et al. (2012) Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance: a population-based study of 9399 Finnish men. J Intern Med 272: 562-572.
37. Makinen VP, Soininen P, Kangas AJ, Forsblom C, Tolonen N, et al. (2012) Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: the FinnDiane Study. J Intern Med.
38. Rogers D, Brown RD, Hahn M, (2005) Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up. J Biomol Screen 10: 682-686.
39. Basili S, Ferroni P, Vieri M, Cardelli P, Ceci F, et al. (1999) Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis 147: 249-252.
40. Sin DD, Man SF, (2003) Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107: 1514-1519.
41. Tisi GM, Conrique A, Barrett-Connor E, Grundy SM, (1981) Increased high density lipoprotein cholesterol in obstructive pulmonary disease (predominant emphysematous type). Metabolism 30: 340-346.
42. Ohta Y, Tsuchihashi T, Onaka U, Hasegawa E, (2010) Clustering of cardiovascular risk factors and blood pressure control status in hypertensive patients. Intern Med 49: 1483-1487.
43. Engstrom G, Lind P, Hedblad B, Wollmer P, Stavenow L, et al. (2002) Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 106: 2555-2560.
44. Wu G, (2009) Amino acids: metabolism, functions, and nutrition. Amino Acids 37: 1-17.
45. Ubhi BK, Cheng KK, Dong J, Janowitz T, Jodrell D, et al. (2012) Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst 8: 3125-3133.
46. Hofford JM, Milakofsky L, Vogel WH, Sacher RS, Savage GJ, et al. (1990) The nutritional status in advanced emphysema associated with chronic bronchitis. A study of amino acid and catecholamine levels. Am Rev Respir Dis 141: 902-908.
47. Schols AM, Deutz NE, Mostert R, Wouters EF, (1993) Plasma amino acid levels in patients with chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 48: 546-548.
48. Engelen MP, Wouters EF, Deutz NE, Menheere PP, Schols AM, (2000) Factors contributing to alterations in skeletal muscle and plasma amino acid profiles in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 72: 1480-1487.
49. Young LH, McNulty PH, Morgan C, Deckelbaum LI, Zaret BL, et al. (1991) Myocardial protein turnover in patients with coronary artery disease. Effect of branched chain amino acid infusion. J Clin Invest 87: 554-560.
50. Berger JS, Sanborn TA, Sherman W, Brown DL, (2004) Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol 94: 649-651.
51. Kim HC, Mofarrahi M, Vassilakopoulos T, Maltais F, Sigala I, et al. (2010) Expression and functional significance of nicotinamide N-methyl transferase in skeletal muscles of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181: 797-805.
52. Biedron R, Ciszek M, Tokarczyk M, Bobek M, Kurnyta M, et al. (2008) 1-Methylnicotinamide and nicotinamide: two related anti-inflammatory agents that differentially affect the functions of activated macrophages. Arch Immunol Ther Exp (Warsz) 56: 127-134.
53. Shariff MI, Ladep NG, Cox IJ, Williams HR, Okeke E, et al. (2010) Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J Proteome Res 9: 1096-1103.
54. Kumari S, Tishel R, Eisenbach M, Wolfe AJ, (1995) Cloning, characterization, and functional expression of acs, the gene which encodes acetyl coenzyme A synthetase in Escherichia coli. J Bacteriol 177: 2878-2886.
55. Chan KM, Decker EA, (1994) Endogenous skeletal muscle antioxidants. Crit Rev Food Sci Nutr 34: 403-426.
56. Klebanov GI, Teselkin Yu O, Babenkova IV, Lyubitsky OB, Rebrova O, et al. (1998) Effect of carnosine and its components on free-radical reactions. Membr Cell Biol 12: 89-99.
57. Qiu Y, Cai G, Su M, Chen T, Liu Y, et al. (2010) Urinary metabonomic study on colorectal cancer. J Proteome Res 9: 1627-1634.
58. Hohmann S, (1991) Characterization of PDC6, a third structural gene for pyruvate decarboxylase in Saccharomyces cerevisiae. J Bacteriol 173: 7963-7969.
59. Kao CC, Hsu JW, Bandi V, Hanania NA, Kheradmand F, et al. (2012) Glucose and pyruvate metabolism in severe chronic obstructive pulmonary disease. J Appl Physiol 112: 42-47.